关于凝血因子VIII和IX产品活性检测差异的思考
新型修饰型凝血因子VIII和IX产品虽延长了给药间隔,但其结构改变影响了功能检测行为。常用的一期凝血法与显色底物法之间常出现活性值不一致,且同一方法内不同试剂盒和试剂也可产生差异。理想情况下所有产品应以WHO国际标准品校准,但修饰产品与WHO国际标准品缺乏互换性,导致效价测定存在问题。
要点
- 新型修饰凝血因子产品的活性检测在一期法与显色法之间常不一致。
- 同一检测方法内不同试剂盒和试剂也可导致效价测定差异。
- 修饰产品与WHO国际标准品缺乏互换性,影响效价校准。
核心结论
- 新型修饰凝血因子产品的结构改变导致其与WHO国际标准品缺乏互换性,造成效价测定差异。
主要发现
- 常用一期凝血法与显色底物法之间常观察到因子活性值不一致。
- 同一检测方法类型内使用不同试剂盒和试剂时也存在效价测定差异。
- 差异归因于修饰产品的结构和功能特性改变,表现为与WHO国际标准品缺乏互换性。
临床怎么用
- 选择检测方法时需考虑以国际标准品校准的检测有效性、效价IU值的含义、患者照护标准、效价与临床实验室回收值的临床相关性及患者安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New modified coagulation factor VIII (FVIII) and factor IX (FIX) products have been designed to improve the treatment of individuals with hemophilia A and B by increasing the interval between dosing. Although these FVIII and FIX molecules have been structurally modified to improve the circulation time, the changes have also influenced their behavior in functional assays in comparison with traditional plasma-derived or recombinant coagulation factors. The assignment of potencies for these products can be problematic because discordance in factor activity values between the commonly used one-stage clotting and chromogenic substrate assays is often observed. Discrepancies in potency assay values also exist when different assay kits and reagents are used in the same assay type. Ideally, all FVIII and FIX products should be calibrated against the World Health Organization (WHO) International Standards (IS) because the assignment of potencies in international units (IU) helps maintain treatment tradition and meaningful references for manufacturers, patients, and clinicians. The discrepant measurements, attributed to the modified structural and functional properties of these products, are manifested in their lack of commutability with the WHO IS for FVIII or FIX. Herein, we discuss the considerations upon which an assay is chosen for potency assignment and postadministration monitoring of a new factor product, which include the validity of the assay calibrated with the IS, the meaning of the potency values in IU, standards of care for patients, clinical relevance between the assigned potency value and recovery value from clinical laboratories, and patient safety.
引用
- Ovanesov MV, Jackson JW, Golding B, et al. Considerations on activity assay discrepancies in factor VIII and factor IX products. J Thromb Haemost. 2021. PMID: 34145730. doi:10.1111/jth.15425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。